Compare AU
Compare DRUG vs. SMLL
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare Currency Hedged ETF (DRUG) and the BetaShares Aust Small Companies Select Fund (Managed Fund) (SMLL). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | SMLL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 9 |
Median incremental investment | $920.50 | $2,091.33 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $4,277.85 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | SMLL | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | SMLL.AX was created on 2017-04-07 by BetaShares. The fund's investment portfolio concentrates primarily on small cap equity. The fund aims to outperform the S&P/ASX Small Ordinaries Accumulation Index over the medium to long term (after fees and expenses) by investing in a portfolio of high quality, profitable small companies. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | CLEANAWAY WASTE MANAGEMENT LTD (4.75 %) INCITEC PIVOT LTD (4.68 %) PERSEUS MINING LTD (3.57 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Materials (26.52 %) Consumer Discretionary (23.94 %) Industrials (14.62 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | Australia (98.15 %) China (1.85 %) |
Management fee | 0.57 % | 0.39 % |
Key Summary
DRUG | SMLL | |
|---|---|---|
Issuer | BetaShares | BetaShares |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.39 % |
Price | $7.95 | $3.61 |
Size | $185.172 million | $94.299 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 5.16 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 11/04/2017 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | SMLL | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 61 | 9 |
Median incremental investment | $920.50 | $2,091.33 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,892.10 | $4,277.85 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | SMLL | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | SMLL |
|---|---|
Lower exposure to AU market | Higher exposure to AU market |
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |